Tiziana Life Sciences (TLSA) announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3-5, 2025, at the Vienna Exhibition and Congress Center in Vienna, Austria. Tiziana’s management team, led by CEO Ivor Elrifi, will also engage in one-on-one partnering meetings with leading biopharma executives and investors. The Company’s presentation will focus on its innovative nasal delivery platform and lead candidate, intranasal foralumab-the only fully human anti-CD3 monoclonal antibody in clinical development. This proprietary approach aims to enhance efficacy, safety, and tolerability over traditional intravenous methods, targeting neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis, Multiple System Atrophy, and early Alzheimer’s disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Advances Nasal Foralumab Study for SPMS
- Tiziana Life Sciences Advances MSA Treatment with Foralumab Nasal Study
- Tiziana Life Sciences Advances Nasal Foralumab Study for Multiple Sclerosis
- Tiziana Life Sciences Reports Interim Results and Expands U.S. Presence
- Tiziana Life Sciences to Attend Life Sciences Innovation Forum 2025 in Riyadh